drugset / Trial / NCT00210574
A Pilot Study of Topiramate in Childhood Absence Epilepsy
Phase 2
Completed
12 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Ortho-McNeil Neurologics, Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Limited data exist on the effectiveness of antiepileptic drugs for treatment of childhood absence epilepsy. Preliminary data suggest that topiramate may be an effective drug for this condition. The present study is designed to provide further evidence of the potential effectiveness of topiramate for childhood absence epilepsy, as well as preliminary information about a potential target dose for future study.
Timeline
- Start
- 2005-03
- Primary completion
- —
- Completion
- 2006-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Topiramate | Small molecule | 9 mg/kg | — |
| Subject | Topiramate | Small molecule | 400 mg | — |